Multivalent nanomaterials: Learning from vaccines and progressing to antigen-specific immunotherapies

Journal of Pharmaceutical Sciences

Volumn 104, Issue 2, 2015, Pages 346-361

  Hartwell, Brittany L ^a   Antunez, Lorena ^b   Sullivan, Bradley P ^b   Thati, Sharadvi ^b   Sestak, Joshua O ^b   Berkland, Cory ^a,b  

^a University of Kansas   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Immune response; Immunotherapy; Multivalency; Nanoparticles; Pharmacokinetics; Polymeric drug delivery systems; Receptor clustering; Targeted drug delivery; Transport; Vaccines

Indexed keywords

ANTIGEN; LIGAND; NANOCARRIER; NANOMATERIAL; POLYMER; VACCINE;

ANTIGEN SPECIFICITY; BIOEQUIVALENCE; DRUG ANTIGENICITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; DRUG TRANSPORT; FLEXIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; LIGAND BINDING; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; REVIEW; RIGIDITY; VACCINE PRODUCTION; CHEMISTRY; IMMUNOLOGY;

ANTIGENS; HUMANS; IMMUNOTHERAPY; LIGANDS; NANOSTRUCTURES; POLYMERS; VACCINES;

EID: 84922895270     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24273     Document Type: Review

References (137)

1. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. 2008. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 83(5):761-769.
2. Klippstein R, Pozo D. 2010. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomed Nan-otechnol Biol Med 6(4):523-529.
3. Brannon-Peppas L, Blanchette JO. 2004. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56(11):1649-1659.
4. Chittasupho C, Siahaan TJ, Vines CM, Berkland C. 2011. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Ther Deliv 2(7):873-889.
5. Chen L, Flies DB. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13(4):227-242.
6. Frauwirth KA, Thompson CB. 2002. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109(3):295-299.
7. Gupta RK, Siber GR. 1995. Adjuvants for human vaccines - Current status, problems and future prospects. Vaccine 13(14):1263-1276.
8. Coffman RL, Sher A, Seder RA. 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503.
9. Fujita H, Meyer N, Akdis M, Akdis CA. 2012. Mechanismsofimmune tolerance to allergens. Chem Immunol Allergy 96:30-38.
10. Szczepanik M. 2011. Mechanisms of immunological tolerance to the antigens of the central nervous system. Skin-induced tolerance as a new therapeutic concept. J Physiol Pharmacol 62(2):159-165.
11. Faria AM, Weiner HL. 2006. Oral tolerance: Therapeutic implications for autoimmune diseases. Clin Dev Immunol 13(2-4):143-157.
12. Peek LJ, Middaugh CR, Berkland C. 2008. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 60(8):915-928.
13. Hogenesch H. 2012. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 3:406.
14. Pashine A, Valiante NM, Ulmer JB. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11 (4 Suppl):S63-S68.
15. Dintzis RZ. 1992. Rational design of conjugate vaccines. Pediatr Res 32(4):376-385.
16. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M. 2006. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40(1):1-9.
17. Leroux-Roels G. 2010. Unmet needs in modern vaccinology: Adjuvants to improve the immune response. Vaccine 28(Suppl 3):C25-C36.
18. Boulikas T. 1991. Relation between carcinogenesis, chromatin structure and poly(ADP-ribosylation) (review). Anticancer Res 11(2):489-527.
19. Bachmann MF, Jennings GT. 2010. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787-796.
20. Cox JC, Coulter AR. 1997. Adjuvants - A classification and review of their modes of action. Vaccine 15(3):248-256.
21. Garcon N, Hem, S, Friede, M. 2012. Evolution of adjuvants across the centuries. In Vaccines; Plotkin S, Orenstein W, Offit P, Ed. 6th ed. St. Louis, MO: Saunders.
22. Owen JA, Punt J, Stranford SA, Jones PP, Kuby J. 2013. Kuby immunology. 7th ed. New York: W.H. Freeman, pp xxvii, 692, 109.
23. Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. 2012. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a plasmodium vivax malaria vaccine. PloS One 7(2):e31472.
24. White RG, Coons AH, Connolly JM. 1955. Studies on antibody production. III. The alum granuloma. J Exp Med 102(1):73-82.
25. Hem SL, Hogenesch H. 2007. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 6(5):685-698.
26. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. 2012. The mechanism of action of MF59 - An innately attractive adjuvant formulation. Vaccine 30(29):4341-4348.
27. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. 2010. Virus-like particles in vaccine development. Expert Rev Vaccines 9(10):1149-1176.
28. Chackerian B, Lenz P, Lowy DR, Schiller JT. 2002. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169(11):6120-6126.
29. Ludwig C, Wagner R. 2007. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 18(6):537-545.
30. Gestwicki JE, Cairo CW, Strong LE, Oetjen KA, Kiessling LL. 2002. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J Am Chem Soc 124(50):14922-14933.
31. Krishnamurthy VM, Estroff LA, Whitesides GM. 2006. Multivalency in ligand design. In Fragment-based approaches in drug discovery; Jahnke W, Erlanson DA, Eds. Weinheim, Germany: Wiley-VCH Verlag GmbH & Company KGaA, pp 11-53.
32. Kiessling LL, Strong LE, Gestwicki JE. 2000. Principles for multivalent ligand design. In Annual reports in medicinal chemistry. Waltham, MA: Academic Press, pp 321-330.
33. Bhanot G. 2004. Results from modeling of B-cell receptors binding to antigen. Prog Biophys Mol Biol 85(2-3):343-352.
34. Puffer EB, Pontrello JK, Hollenbeck JJ, Kink JA, Kiessling LL. 2007. Activating B cell signaling with defined multivalent ligands. ACS Chem Biol 2(4):252-262.
35. Hat B, Kazmierczak B, Lipniacki T. 2011. B cell activation triggered by the formation of the small receptor cluster: A computational study. PLoS Comput Biol 7(10):e1002197.
36. Crocker PR, FeiziT. 1996. Carbohydrate recognition systems: Functional triads in cell-cell interactions. Curr Opin Struct Biol 6(5):679-691.
37. Lee R, Lee Y. 1994. Enhanced biochemical affinities of multivalent neoglycoconjugates. San Diego, California: Academic Press, pp 23-50.
38. Lin CC, Yeh YC, Yang CY, Chen GF, Chen YC, Wu YC, Chen CC. 2003. Quantitative analysis of multivalent interactions of carbohydrate-encapsulated gold nanoparticles with concanavalin A. Chem Commun (23):2920-2921.
39. Chien YY, Jan MD, Adak AK, Tzeng HC, Lin YP, Chen YJ, Wang KT, Chen CT, Chen CC, Lin CC. 2008. Globotriose-functionalized gold nanoparticles as multivalent probes for Shiga-like toxin. Chembiochem 9(7):1100-1109.
40. Kiessling LL, Gestwicki JE, Strong LE. 2000. Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol 4(6):696-703.
41. Cairo CW, Gestwicki JE, Kanai M, Kiessling LL. 2002. Control of multivalent interactions by binding epitope density. J Am Chem Soc 124(8):1615-1619.
42. Minguet S, Dopfer EP, Schamel WW. 2010. Low-valency, but not monovalent, antigens trigger the B-cell antigen receptor (BCR). Int Immunol 22(3):205-212.
43. Griffith BR, Allen BL, Rapraeger AC, Kiessling LL. 2004.A polymer scaffold for protein oligomerization. J Am Chem Soc 126(6):1608-1609.
44. Qhattal HS, Hye T, Alali A, Liu X. 2014. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano 8(6):5423-5440.
45. Qhattal HS, Liu X. 2011. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm 8(4):1233-1246.
46. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. 2003. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 9(17):6551-6559.
47. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. 2008. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105(7):2586-2591.
48. McNeeley KM, Annapragada A, Bellamkonda RV. 2007. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 18(38):385101.
49. Said Hassane F, Phalipon A, Tanguy M, Guerreiro C, Belot F, Frisch B, Mulard LA, Schuber F. 2009. Rational design and immunogenicity of liposome-based diepitope constructs: Application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen. Vaccine 27(39):5419-5426.
50. Champion JA, Katare YK, Mitragotri S. 2007. Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 121(1-2):3-9.
51. Supersaxo A, Hein WR, Steffen H. 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7(2):167-169.
52. Kota J, Machavaram KK, McLennan DN, Edwards GA, Porter CJ, Charman SA. 2007. Lymphatic absorption of subcutaneously administered proteins: Influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos 35(12):2211-2217.
53. Oussoren C, Zuidema J, Crommelin DJ, Storm G. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1328(2):261-272.
54. Noh YW, Kong SH, Choi DY, Park HS, Yang HK, Lee HJ, Kim HC, Kang KW, Sung MH, Lim YT. 2012. Near-infrared emitting polymer nanoges for efficient sentinel lymph node mapping. ACS Nano 6(9):7820-7831.
55. Niikura K, Matsunaga T, Suzuki T, Kobayashi S, Yamaguchi H, Orba Y, Kawaguchi A, Hasegawa H, Kajino K, Ninomiya T, Ijiro K, Sawa H. 2013. Gold nanoparticles as a vaccine platform: Influence of size and shape on immunological responses in vitro and in vivo. ACS Nano 7(5):3926-3938.
56. Oyewumi MO, Kumar A, Cui Z. 2010. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9(9):1095-1107.
57. Wooden SK, Kapur RP, Lee AS. 1988. The organization of the rat GRP78 gene and A23187-induced expression of fusion gene products targeted intracellularly. Exp Cell Res 178(1):84-92.
58. Wang H, Wang J, Deng X, Sun H, Shi Z, Gu Z, Liu Y, Zhao Y. 2004. Biodistribution of carbon single-wall carbon nanotubes in mice. J Nanosci Nanotechnol 4(8):1019-1024.
59. Yoo JW, Doshi N, Mitragotri S. 2011. Adaptive micro and nanoparticles: Temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev 63(14-15):1247-1256.
60. Christian DA, Cai S, Garbuzenko OB, Harada T, Zajac AL, Minko T, Discher DE. 2009. Flexible filaments for in vivo imaging and delivery: Persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol Pharm 6(5):1343-1352.
61. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. 2007. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2(4):249-255.
62. Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, Liu X, Ferrari M. 2010. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release 141(3):320-327.
63. Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, Schuchman EH, Mitragotri S, Muzykantov VR. 2008. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 16(8):1450-1458.
64. Li S, Nickels J, Palmer AF. 2005. Liposome-encapsulated actin-hemoglobin (LEAcHb) artificial blood substitutes. Biomaterials 26(17):3759-3769.
65. Kolhar P, Anselmo AC, Gupta V, Pant K, Prabhakarpandian B, Ruoslahti E, Mitragotri S. 2013. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Nat Acad Sci USA 110(26):10753-10758.
66. Barua S, Yoo JW, Kolhar P, Wakankar A, Gokam YR, Mitragotri S. 2013. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Nat Acad Sci USA 110(9):3270-3275.
67. Champion JA, Mitragotri S. 2009. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 26(1):244-249.
68. Howard M, Zern BJ, Anselmo AC, Shuvaev W, Mitragotri S, Muzykantov V. 2014. Vascular targetingofnanocarriers: Perplexing aspects of the seemingly straightforward paradigm. ACS Nano 8(5):4100-4132.
69. Champion JA, Mitragotri S. 2006. Role of target geometry in phagocytosis. Proc Nat Acad Sci USA 103(13):4930-4934.
70. Sharma G, Valenta DT, Altman Y, Harvey S, Xie H, Mitragotri S, Smith JW. 2010. Polymer particle shape independently influences binding and internalization by macrophages. J Control Release 147(3):408-412.
71. Park K. 2010. Effect of shape and size of polymer particles on cellular internalization. J Control Release 147(3):313.
72. Heegaard PM, Boas U, Sorensen NS. 2010. Dendrimers for vaccine and immunostimulatory uses. A review. Bioconjug Chem 21(3):405-418.
73. Boas U, Heegaard PM. 2004. Dendrimers in drug research. Chem Soc Rev 33(1):43-63.
74. Hasegawa T, Kondoh S, Matsuura K, Kobayashi K. 1999. Rigid helical poly(glycosyl phenyl isocyanide)s: Synthesis, conformational analysis, and recognition by lectins. Macromolecules 32(20):6595-6603.
75. Beningo KA, Wang YL. 2002. Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. J Cell Sci 115(Pt 4):849-856.
76. Venkataraman S, Hedrick JL, Ong ZY, Yang C, Ee PL, Hammond PT, Yang YY. 2011. The effects of polymeric nanostructure shape on drug delivery. Adv Drug Deliv Rev 63(14-15):1228-1246.
77. Kim Y, Dalhaimer P, Christian DA, Discher DE. 2005. Polymeric worm micelles as nano-carriers for drug delivery. Nanotechnology 16(7):484-491.
78. Dintzis HM, Dintzis RZ, Vogelstein B. 1976. Molecular determinants of immunogenicity: The immunon model of immune response. Proc Nat Acad Sci USA 73(10):3671-3675.
79. Dintzis HM, Dintzis RZ. 1990. Antigens as immunoregulators. Immunol Rev 115:243-250.
80. Dintzis RZ, Middleton MH, Dintzis HM. 1985. Inhibition of anti-DNP antibody formation by high doses of DNP-polyacrylamide molecules; effects of hapten density and hapten valence. J Immunol 135(1):423-427.
81. Siliciano RF, Colello RM, Keegan AD, Dintzis RZ, Dintzis HM, Shin HS. 1985. Antigen valence determines the binding of nominal antigen to cytolytic T cell clones. J Exp Med 162(2):768-773.
82. Symer DE, Dintzis RZ, Diamond DJ, Dintzis HM. 1992. Inhibition or activation of human T cell receptor transfectants is controlled by defined, soluble antigen arrays. J Exp Med 176(5):1421-1430.
83. Symer DE, Reim J, Dintzis RZ, Voss EW Jr, Dintzis HM. 1995. Durable elimination of high affinity, T cell-dependent antibodies by low molecular weight antigen arrays in vivo. J Immunol 155(12):5608-5616.
84. Reim JW, Symer DE, Watson DC, Dintzis RZ, Dintzis HM. 1996. Low molecular weight antigen arrays delete high affinity memory B cells without affecting specific T-cell help. Mol Immunol 33(17-18):1377-1388.
85. Hafler DA, Weiner HL. 1995. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 144:75-107.
86. Watson DC, Reim J, Dintzis HM. 1996. Suppression of the antibody response to a polymorphic peptide from the platelet alloantigen integrin beta3 with low molecular weight antigen arrays. J Immunol 156(7):2443-2450.
87. Dintzis RZ, Middleton MH, Dintzis HM. 1983. Studies on the immunogenicity and tolerogenicity of T-independent antigens. J Immunol 131(5):2196-2203.
88. Dintzis RZ, Vogelstein B, Dintzis HM. 1982. Specific cellular stimulation in the primary immune response: Experimental test of a quantized model. Proc Natl Acad Sci USA 79(3):884-888.
89. Gestwicki JE, Strong LE, Kiessling LL. 2000. Tuning chemotactic responses with synthetic multivalent ligands. Chem Biol 7(8):583-591.
90. Snippe H, van Houte AJ, Lizzio EF, Willers JM, Merchant B. 1982. Characterization of immunogenic properties of haptenated liposomal model membranes in mice. VI. Response in B-cell-defective CBA/N mice. Immunology 45(3):545-551.
91. Van Houte AJ, Snippe H, Willers JM. 1979. Characterization of immunogenic properties of haptenated liposomal model membranes in mice. I. Thymus independence of the antigen. Immunology 37(2):505-514.
92. Snippe H, Van Houte AJ, Janssen A, Lizzio EF, Willers JM, Merchant B. 1982. Characterization of immunogenic properties of haptenated liposomal model memranes in mice. VII. Synergistic responses to haptenated liposomes and haptenated thymus-dependent antigens in CBA/N mice. Immunology 45(4):613-620.
93. Gestwicki JE, Strong LE, Cairo CW, Boehm FJ, Kiessling LL. 2002. Cell aggregation by scaffolded receptor clusters. Chem Biol 9(2):163-169.
94. Andre S, Ortega PJ, Perez MA, Roy R, Gabius HJ. 1999. Lactose-containing starburst dendrimers: Influence of dendrimer generation and binding-site orientation of receptors (plant/animal lectins and immunoglobulins) on binding properties. Glycobiology 9(11):1253-1261.
95. Dintzis HM, Dintzis RZ. 1992. Profound specific suppression by antigen of persistent IgM, IgG, and IgE antibody production. Proc Natl Acad Sci USA 89(3):1113-1117.
96. Dintzis RZ, Okajima M, Middleton MH, Greene G, Dintzis HM. 1989. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol 143(4):1239-1244.
97. Diner UE, Kunimoto D, Diener E. 1979. Carboxymethyl cellulose, a nonimmunogenic hapten carrier with tolerogenic properties. J Immunol 122(5):1886-1891.
98. Desaymard C. 1977. Role of epitope density in the induction of immunity and tolerance with thymus-independent antigens. IV. Selective tolerance and IgE response by DNP-levan conjugates. Eur J Immunol 7(9):646-649.
99. Desaymard C, Howard JG. 1975. Role of epitope density in the induction of immunity and tolerance with thymus-independent antigens. II. Studies with 2,4-dinitrophenyl conjugates in vivo. Eur J Immunol 5(8):541-545.
100. Desaymard C, Feldmann M. 1975. Role of epitope density in the induction of immunity and tolerance with thymus-independent antigens. I. Studies with 2,4-dinitrophenyl conjugates in vitro. Eur J Immunol 5(8):537-541.
101. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, Getts MT, Pleiss M, Luo X, King NJ, Shea LD, Miller SD. 2012. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 30(12):1217-1224.
102. Hunter Z, McCarthy DP, Yap WT, Harp CT, Getts DR, Shea LD, Miller SD. 2014. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 8(3):2148-2160.
103. Wegmann KW, Wagner CR, Whitham RH, Hinrichs DJ. 2008. Synthetic Peptide dendrimers block the development and expression of experimental allergic encephalomyelitis. J Immunol 181(5):3301-3309.
104. Choi S-K, Mammen M, Whitesides GM. 1997. Generation and in situ evaluation of libraries of poly(acrylic acid) presenting sialosides as side chains as polyvalent inhibitors of influenza-mediated hemagglutination. J Am Chem Soc 119(18):4103-4111.
105. Brinas RP, Sundgren A, Sahoo P, Morey S, Rittenhouse-Olson K, Wilding GE, Deng W, Barchi JJ Jr. 2012. Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines. Bioconjug Chem 23(8):1513-1523.
106. Courtney AH, Puffer EB, Pontrello JK, Yang ZQ, Kiessling LL. 2009. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc Natl Acad Sci USA 106(8):2500-2505.
107. Duong BH, Tian H, Ota T, Completo G, Han S, Vela JL, Ota M, Kubitz M, Bovin N, Paulson JC, Nemazee D. 2010. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J Exp Med 207(1):173-187.
108. Sestak J, Mullins M, Northrup L, Thati S, Forrest ML, Siahaan TJ, Berkland C. 2013. Single-step grafting of aminooxy-peptides to hyaluronan: A simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis. J Control Release 168(3):334-340.
109. Pfrengle F, Macauley MS, Kawasaki N, Paulson JC. 2013. Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22. J Immunol 191(4):1724-1731.
110. Muller J, NitschkeL. 2014. The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol 10(7):422-428.
111. Thomann JS, Heurtault B, Weidner S, Braye M, Beyrath J, Fournel S, Schuber F, Frisch B. 2011. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 32(20):4574-4583.
112. Sestak JO, Sullivan BP, Thati S, Northrup L, Hartwell B, Antunez L, Forrest ML, Vines CM, Siahaan TJ, Berkland C. 2014. Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays inexperimental autoimmune encephalomyelitis. Mol Ther Methods Clin Dev 1. doi:10.1038/mtm.2014.8
113. Marlin SD, Springer TA. 1987. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51(5):813-819.
114. Makgoba MW, Sanders ME, Ginther Luce GE, Dustin ML, Springer TA, Clark EA, Mannoni P, Shaw S. 1988. ICAM-1 a ligand for LFA-1 dependent adhesion of B, T and myeloid cells. Nature 331(6151):86-88.
115. Dustin ML, Springer TA. 1988. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 107(1):321-331.
116. Dustin ML, Springer TA. 1989. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341(6243):619-624.
117. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. 1990. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144(12):4579-4586.
118. Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Knutson KL, Pease LR. 2007. Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: Dependence on TCR: peptide-MHC interaction, ICAM-1, IL-12, and IFN-gamma. J Immunol 178(6):3583-3592.
119. Northrup L, Sestak JO, Sullivan BP, Thati S, Hartwell BL, Siahaan TJ, Vines CM, Berkland C. 2014. Co-delivery of autoantigen and B7 pathway modulators suppresses experimental autoimmune encephalomyelitis. AAPS J 16(6):1204-1213.
120. Marradi M, Chiodo F, Garcia I, Penades S. 2013. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem Soc Rev 42(11):4728-4745.
121. Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ. 2012. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 109(28):11270-11275.
122. Macauley MS, Pfrengle F, Rademacher C, Nycholat CM, Gale AJ, von Drygalski A, Paulson JC. 2013. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest 123(7):3074-3083.
123. Jun JE, Goodnow CC. 2003. Scaffolding of antigen receptors for immunogenic versus tolerogenic signaling. Nat Immunol 4(11):1057-1064.
124. Baxter AG, Hodgkin PD. 2002. Activation rules: The two-signal theories of immune activation. Nat Rev Immunol 2(6):439-446.
125. Dresser DW, Mitchison NA. 1968. The mechanism of immunological paralysis. Adv Immunol 8:129-181.
126. Goodnow CC. 1996. Balancing immunity and tolerance: Deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 93(6):2264-2271.
127. Grossman Z, Paul WE. 1992. Adaptive cellular interactions in the immune system: The tunable activation threshold and the significance ofsubthreshold responses. Proc Natl Acad Sci USA 89(21):10365-10369.
128. Redmond WL, Marincek BC, Sherman LA. 2005. Distinct requirements for deletion versus anergy during CD8 Tcell peripheral tolerance in vivo. J Immunol 174(4):2046-2053.
129. Basten A, Silveira PA. 2010. B-cell tolerance: Mechanisms and implications. Curr Opin Immunol 22(5):566-574.
130. Junt T, Scandella E, Ludewig B. 2008. Form follows function: Lymphoid tissue microarchitecture in antimicrobial immune defence. Nat Rev Immunol 8(10):764-775.
131. von Moos S, Kundig TM, Senti G. 2011. Novel administration routes for allergen-specific immunotherapy: A review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am 31(2):391-406.
132. Smarr CB, Bryce PJ, Miller SD. 2013. Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit Rev Immunol 33(5):389-414.
133. Kourtis IC, Hirosue S, de Titta A, Kontos S, Stegmann T, Hubbell JA, Swartz MA. 2013. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PloS One 8(4):e61646.
134. Fong CL, Mok CL, Hui KM. 2006. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression. Gene Ther 13(3):245-256.
135. Senti G, Johansen P, Kundig TM. 2009. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 9(6):537-543.
136. Akdis CA, Akdis M. 2011. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127(1):18-27.
137. Bousquet J, Lockey R, Malling HJ. 1998. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102(4 Pt 1):558-562.